These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28336343)

  • 1. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
    Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
    Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
    Katz G; Shainberg A; Hochhauser E; Kurtzwald-Josefson E; Issac A; El-Ani D; Aravot D; Afek A; Seidman JG; Seidman CE; Eldar M; Arad M
    Biochem Pharmacol; 2013 Dec; 86(11):1576-83. PubMed ID: 24070655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.
    Denegri M; Bongianino R; Lodola F; Boncompagni S; De Giusti VC; Avelino-Cruz JE; Liu N; Persampieri S; Curcio A; Esposito F; Pietrangelo L; Marty I; Villani L; Moyaho A; Baiardi P; Auricchio A; Protasi F; Napolitano C; Priori SG
    Circulation; 2014 Jun; 129(25):2673-81. PubMed ID: 24888331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
    Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
    Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
    Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
    Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
    Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
    Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
    Valle G; Arad M; Volpe P
    J Muscle Res Cell Motil; 2020 Sep; 41(2-3):251-258. PubMed ID: 32902830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
    Viatchenko-Karpinski S; Terentyev D; Györke I; Terentyeva R; Volpe P; Priori SG; Napolitano C; Nori A; Williams SC; Györke S
    Circ Res; 2004 Mar; 94(4):471-7. PubMed ID: 14715535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias.
    Denegri M; Avelino-Cruz JE; Boncompagni S; De Simone SA; Auricchio A; Villani L; Volpe P; Protasi F; Napolitano C; Priori SG
    Circ Res; 2012 Mar; 110(5):663-8. PubMed ID: 22298808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
    Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
    J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
    Faber GM; Rudy Y
    Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catecholaminergic polymorphic ventricular tachycardia (and seizure) caused by a novel homozygous likely pathogenic variant in CASQ2 gene.
    Askarinejad A; Esmaeili S; Dalili M; Biglari A; Kohansal E; Maleki M; Kalayinia S
    Gene; 2024 Feb; 895():148012. PubMed ID: 37995796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.
    Dirksen WP; Lacombe VA; Chi M; Kalyanasundaram A; Viatchenko-Karpinski S; Terentyev D; Zhou Z; Vedamoorthyrao S; Li N; Chiamvimonvat N; Carnes CA; Franzini-Armstrong C; Györke S; Periasamy M
    Cardiovasc Res; 2007 Jul; 75(1):69-78. PubMed ID: 17449018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.
    Katz G; Khoury A; Kurtzwald E; Hochhauser E; Porat E; Shainberg A; Seidman JG; Seidman CE; Lorber A; Eldar M; Arad M
    Heart Rhythm; 2010 Nov; 7(11):1676-82. PubMed ID: 20620233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.
    Kurtzwald-Josefson E; Hochhauser E; Katz G; Porat E; Seidman JG; Seidman CE; Chepurko Y; Shainberg A; Eldar M; Arad M
    J Appl Physiol (1985); 2012 Dec; 113(11):1677-83. PubMed ID: 23042908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
    Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
    Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
    Kalyanasundaram A; Viatchenko-Karpinski S; Belevych AE; Lacombe VA; Hwang HS; Knollmann BC; Gyorke S; Periasamy M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H253-61. PubMed ID: 21984545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
    Faggioni M; Kryshtal DO; Knollmann BC
    Pediatr Cardiol; 2012 Aug; 33(6):959-67. PubMed ID: 22421959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.